Moderate hypo-fractionation

RADIATION2 trials

Sponsors

Tata Memorial Centre, Umeå University

Conditions

Metastatic CancerProstate AdenocarcinomaProstate CancerRadiotherapy Side Effect

Unknown Phase

Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial)

Active, not recruitingNCT03561961

Tata Memorial CentreProstate Adenocarcinoma

Start: 2018-05-24End: 2035-03-31Updated: 2025-02-13

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

RecruitingNCT04612907

Umeå UniversityMetastatic Cancer, Prostate Cancer, Radiotherapy Side Effect

Start: 2022-10-31End: 2032-09-30Target: 420Updated: 2024-02-28

Related Papers

Different fractionation schedules of radiotherapy to the primary tumor in metastatic hormone sensitive prostate cancer (Hypo-M1).

Journal of Clinical Oncology2022-02-16

Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)

BMJ Open2020-02-0127 citations